Tonix Pharmaceuticals Holding Corp (TNXP) shares surged on Tuesday after securing a $34 million research collaboration contract with X-Chem from the U.S. Department of Defense. The collaboration will accelerate the development of Tonix’s broad-spectrum antiviral program, TNX-4200, utilizing AI and machine learning technology.